UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?

Bioorganic & medicinal chemistry letters, 2019-12, Vol.29 (23), p.126731-126731, Article 126731

2019

Volltextzugriff (PDF)

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis

Journal of antibiotics, 2015-11, Vol.68 (11), p.711-714

2015

Volltextzugriff (PDF)

Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development

Pharmaceuticals (Basel, Switzerland), 2024-07, Vol.17 (7), p.962

2024

Volltextzugriff (PDF)

Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances

Pharmaceuticals (Basel, Switzerland), 2023-01, Vol.16 (2), p.203

2023

Volltextzugriff (PDF)

MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

Antimicrobial Agents and Chemotherapy, 2012-01, Vol.56 (1), p.324-331

2012

Volltextzugriff (PDF)

MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target

Mini reviews in medicinal chemistry, 2016-01, Vol.16 (16), p.1274

2016

Volltextzugriff (PDF)

SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis

Pharmaceuticals (Basel, Switzerland), 2020-08, Vol.13 (9), p.227

2020

Volltextzugriff (PDF)

Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery

Pharmaceutics, 2024-05, Vol.16 (6), p.725

2024

Volltextzugriff (PDF)

(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors

European journal of medicinal chemistry, 2016-07, Vol.117, p.292-300

2016

Volltextzugriff (PDF)

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection

PloS one, 2013-02, Vol.8 (2), p.e56980

2013

Volltextzugriff (PDF)

Metabolomic Profiling of Fresh Goji (Lycium barbarum L.) Berries from Two Cultivars Grown in Central Italy: A Multi-Methodological Approach

Molecules (Basel, Switzerland), 2021-09, Vol.26 (17), p.5412

2021

Volltextzugriff (PDF)

In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis

International immunopharmacology, 2018-11, Vol.64, p.86-100

2018

Volltextzugriff (PDF)

Antiviral Mechanisms of N -Phenyl Benzamides on Coxsackie Virus A9

Pharmaceutics, 2023-03, Vol.15 (3), p.1028

2023

Volltextzugriff (PDF)

A novel antimycobacterial compound acts as an intracellular iron chelator

Antimicrobial agents and chemotherapy, 2015-04, Vol.59 (4), p.2256-2264

2015

Volltextzugriff (PDF)

In Vitro Effects of VA441, a New Selective Cyclooxygenase-2 Inhibitor, on Human Osteoarthritic Chondrocytes exposed to IL-1β

Journal of Pharmacological Sciences, 2012, Vol.120(1), pp.6-14

2012

Volltextzugriff (PDF)

Introduction to COX inhibitors

Future medicinal chemistry, 2018-08, Vol.10 (15), p.1737-1740

Biava, Mariangela

2018

Volltextzugriff (PDF)

Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment

Pharmaceutics, 2022-03, Vol.14 (3), p.610

2022

Volltextzugriff (PDF)

A Novel Class of Dual-Acting DCH-CORMs Counteracts Oxidative Stress-Induced Inflammation in Human Primary Tenocytes

Antioxidants, 2021-11, Vol.10 (11), p.1828

2021

Volltextzugriff (PDF)

Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells

Bioorganic & medicinal chemistry letters, 2011-10, Vol.21 (19), p.5928-5933

2011

Volltextzugriff (PDF)

Chocolate Consumers and Lymphocyte-to-Monocyte Ratio: A Working Hypothesis from a Preliminary Report of a Pilot Study in Celiac Subjects

Antioxidants, 2019-10, Vol.8 (10), p.440

2019

Volltextzugriff (PDF)

BM 212 and its derivatives as a new class of antimycobacterial active agents

Current medicinal chemistry, 2002-11, Vol.9 (21), p.1859

Biava, Mariangela

2002

Volltextzugriff (PDF)

Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy

Seminars in cancer biology, 2021-02, Vol.69, p.150-165

2021

Volltextzugriff (PDF)

1,5-Diarylpyrrole-3-acetic Acids and Esters as Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors

Journal of medicinal chemistry, 2005-05, Vol.48 (9), p.3428-3432

2005

Volltextzugriff (PDF)

Overcoming drug resistance for tuberculosis

Future microbiology, 2015-11, Vol.10 (11), p.1735-1741

2015

Volltextzugriff (PDF)

Antimycobacterial compounds. Optimization of the BM 212 structure, the lead compound for a new pyrrole derivative class

Bioorganic & medicinal chemistry, 2005-02, Vol.13 (4), p.1221-1230

2005

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(92)

Publikationsform

Artikel
(97)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(71)
Pharmacology & Pharmacy
(64)
Chemistry, Medicinal
(50)
Humans
(37)
Chemistry
(28)
Animals
(26)
Physical Sciences
(23)
Pyrroles - Pharmacology
(23)
Structure-Activity Relationship
(22)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Pharmacology. Drug Treatments
(20)
Pyrroles - Chemistry
(20)
Chemistry, Organic
(19)
Tuberculosis
(18)
Antitubercular Agents - Pharmacology
(17)
Models, Molecular
(17)
Mycobacterium Tuberculosis - Drug Effects
(15)
Cyclooxygenase 2 Inhibitors - Pharmacology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis

Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development

Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances

MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target

SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis

Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery

(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection

Metabolomic Profiling of Fresh Goji (Lycium barbarum L.) Berries from Two Cultivars Grown in Central Italy: A Multi-Methodological Approach

In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis

Antiviral Mechanisms of N -Phenyl Benzamides on Coxsackie Virus A9

A novel antimycobacterial compound acts as an intracellular iron chelator

In Vitro Effects of VA441, a New Selective Cyclooxygenase-2 Inhibitor, on Human Osteoarthritic Chondrocytes exposed to IL-1β

Introduction to COX inhibitors

Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment

A Novel Class of Dual-Acting DCH-CORMs Counteracts Oxidative Stress-Induced Inflammation in Human Primary Tenocytes

Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells

Chocolate Consumers and Lymphocyte-to-Monocyte Ratio: A Working Hypothesis from a Preliminary Report of a Pilot Study in Celiac Subjects

BM 212 and its derivatives as a new class of antimycobacterial active agents

Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy

1,5-Diarylpyrrole-3-acetic Acids and Esters as Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors

Overcoming drug resistance for tuberculosis

Antimycobacterial compounds. Optimization of the BM 212 structure, the lead compound for a new pyrrole derivative class

Suchergebnisse filtern